Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia

J Clin Oncol. 1986 Jun;4(6):906-11. doi: 10.1200/JCO.1986.4.6.906.

Abstract

Eleven patients with Philadelphia chromosome (Ph1)-positive chronic myelogenous leukemia (CML) in blast crisis (ten patients) or accelerated disease (one patient) were treated with piperazinedione (PIP) and fractionated total body irradiation (TBI) followed by autologous bone marrow transplantation (ABMT). Three patients were transplanted with marrow from which the Ph1 clone had been eradicated by prior intensive chemotherapy. All patients responded with disappearance of blasts in bone marrow and peripheral blood. Six patients achieved a second chronic phase lasting 3 to 14 months (median, 6 months). Two patients had incomplete recovery, and three patients failed to engraft and died from infection. Transplantation with Ph1-negative bone marrow did not improve response duration or survival. Recurrence of blast crisis and incomplete engraftment continue to be the two major problems in this patient group, and more active regimens need to be investigated.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibiotics, Antineoplastic / therapeutic use*
  • Bone Marrow / ultrastructure
  • Bone Marrow Transplantation*
  • Female
  • Freezing
  • Granulocytes
  • Hematopoietic Stem Cells / ultrastructure
  • Humans
  • Karyotyping
  • Leukemia, Myeloid / blood
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / therapy*
  • Leukocyte Count
  • Male
  • Middle Aged
  • Philadelphia Chromosome
  • Piperazines / therapeutic use*
  • Platelet Count
  • Preservation, Biological
  • Splenectomy
  • Whole-Body Irradiation

Substances

  • Antibiotics, Antineoplastic
  • Piperazines
  • 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione